Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2020

01-01-2020 | Hepatocellular Carcinoma | Original Article

Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C

Authors: Charlotte E. Costentin, Philippe Sogni, Bruno Falissard, Jean-Claude Barbare, Noelle Bendersky, Olivier Farges, Nathalie Goutte

Published in: Digestive Diseases and Sciences | Issue 1/2020

Login to get access

Abstract

Background

Data on alcohol-related HCC are limited.

Aims

Our aim was to describe the incidence, management, and prognosis of alcohol compared to Hepatitis C (HCV)-related HCC at a national level.

Methods

Incident cases of HCC were identified in French healthcare databases between 2009 and 2012 and analyzed retrospectively. Demographic data, type, location, and annual HCC-caseload of the hospitals where patients were first managed were retrieved. Survival of incident cases was computed from the time of diagnosis and adjusted for potential confounding variables.

Results

The study population included 14,060 incident cases of alcohol and 2581 HCV-related HCC. Alcohol-related HCC was more frequent than HCV-related HCC (29.37 and 5.39/100,000 adults/year, respectively) with an heterogeneous distribution on the French territory. The optimal treatment was less frequently curative (20.5% vs 35.9%; p < 0.001), and survival was significantly shorter (9.5 [9.0–10.0] versus 16.8 [15.5–18.7] months p < 0.001) in alcohol compared to HCV-related HCC, with marked variations between regions for a given risk factor. In multivariable analysis in the whole study population, curative treatment was a strong predictor of survival (adjusted HR 0.28 [0.27–0.30] months p < 0.001). Being managed at least once in a teaching hospital during follow-up was independently associated with receiving a curative treatment and survival.

Conclusion

In France, incidence of alcohol-related HCC is high and prognosis is poor compared to HCV-related HCC, with marked variations between regions. These results should guide future health policy initiatives pertaining to HCC care. Importantly, increasing patient’ referral in expert centers could increase chances to receive curative treatment and improve outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3:1683–1691.PubMedPubMedCentral Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 2017;3:1683–1691.PubMedPubMedCentral
3.
go back to reference EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef
4.
go back to reference Rosa I, Denis J, Lesgourgues B, et al. A french multicentric longitudinal descriptive study of hepatocellular carcinoma management. The CHANGH cohort: preliminary results. Hepatology 2010:1144A (Abstract). Rosa I, Denis J, Lesgourgues B, et al. A french multicentric longitudinal descriptive study of hepatocellular carcinoma management. The CHANGH cohort: preliminary results. Hepatology 2010:1144A (Abstract).
6.
go back to reference Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017;66:537–544.CrossRefPubMed Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017;66:537–544.CrossRefPubMed
7.
go back to reference Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718–735.CrossRefPubMed Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718–735.CrossRefPubMed
9.
go back to reference Bucci L, Garuti F, Camelli V, et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43:385–399.CrossRefPubMed Bucci L, Garuti F, Camelli V, et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther. 2016;43:385–399.CrossRefPubMed
10.
go back to reference Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS ONE. 2018;13:e0204412.CrossRefPubMedPubMedCentral Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS ONE. 2018;13:e0204412.CrossRefPubMedPubMedCentral
11.
go back to reference Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and nonalcoholic fatty liver disease among patients with cirrhosis: an observational study. PLoS ONE. 2017;12:e0186715.CrossRefPubMedPubMedCentral Marot A, Henrion J, Knebel JF, Moreno C, Deltenre P. Alcoholic liver disease confers a worse prognosis than HCV infection and nonalcoholic fatty liver disease among patients with cirrhosis: an observational study. PLoS ONE. 2017;12:e0186715.CrossRefPubMedPubMedCentral
12.
go back to reference Costentin C, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective nationwide study. Cancer. 2018;124:1964–1972.CrossRefPubMed Costentin C, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective nationwide study. Cancer. 2018;124:1964–1972.CrossRefPubMed
13.
go back to reference Ganne-Carrié N, Chaffaut C, Bourcier V, CIRRAL Group, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69:1274–1283.CrossRefPubMed Ganne-Carrié N, Chaffaut C, Bourcier V, CIRRAL Group, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69:1274–1283.CrossRefPubMed
14.
go back to reference Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.CrossRefPubMed Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–209.CrossRefPubMed
15.
go back to reference Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.PubMed Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422.PubMed
16.
go back to reference Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–1310.CrossRefPubMed Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–1310.CrossRefPubMed
17.
go back to reference Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.CrossRefPubMed Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291–297.CrossRefPubMed
18.
go back to reference Sato T, Tateishi R, Yoshida H, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544–550.CrossRefPubMedPubMedCentral Sato T, Tateishi R, Yoshida H, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544–550.CrossRefPubMedPubMedCentral
19.
go back to reference Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793–799.CrossRefPubMedPubMedCentral Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793–799.CrossRefPubMedPubMedCentral
20.
go back to reference Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J. 2004;10:317–325.CrossRefPubMed Yu EW, Chie WC, Chen TH. Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients? Cancer J. 2004;10:317–325.CrossRefPubMed
21.
go back to reference Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734–744.CrossRefPubMed Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol. 2002;97:734–744.CrossRefPubMed
22.
go back to reference Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006;26:543–551.CrossRefPubMed Tanaka H, Nouso K, Kobashi H, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int. 2006;26:543–551.CrossRefPubMed
23.
go back to reference Wong GL, Wong VW, Tan GM, et al. Surveillance program for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79–87.CrossRefPubMed Wong GL, Wong VW, Tan GM, et al. Surveillance program for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int. 2008;28:79–87.CrossRefPubMed
25.
go back to reference El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992–997.CrossRefPubMed El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60:992–997.CrossRefPubMed
26.
go back to reference Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016;65:693–701.CrossRefPubMed Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016;65:693–701.CrossRefPubMed
27.
go back to reference Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol. 2016;65:1148–1154.CrossRefPubMedPubMedCentral Mittal S, Kanwal F, Ying J, et al. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort. J Hepatol. 2016;65:1148–1154.CrossRefPubMedPubMedCentral
28.
go back to reference Johnson P, Berhane S, Kagebayashi C, et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441–447.CrossRefPubMedPubMedCentral Johnson P, Berhane S, Kagebayashi C, et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116:441–447.CrossRefPubMedPubMedCentral
29.
go back to reference Costentin C, Layese R, Bourcier V, et al. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. Gastroenterology. 2018;155:e10.CrossRef Costentin C, Layese R, Bourcier V, et al. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. Gastroenterology. 2018;155:e10.CrossRef
30.
go back to reference Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2014;35:1862–1871.CrossRef Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2014;35:1862–1871.CrossRef
31.
go back to reference Eskesen AN, Bjøro K, Aandahl EM, Line PD, Melum E. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway—a population-based cohort study. Cancer Epidemiol. 2014;38:741–747.CrossRefPubMed Eskesen AN, Bjøro K, Aandahl EM, Line PD, Melum E. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway—a population-based cohort study. Cancer Epidemiol. 2014;38:741–747.CrossRefPubMed
32.
33.
go back to reference Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65:875–884.CrossRefPubMed Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65:875–884.CrossRefPubMed
35.
go back to reference Barbare JC, Franco D, André T, et al. Should cases of hepatocellular carcinoma be discussed by non specialize multidisciplinary team meetings? Bull Cancer. 2014;101:558–563.CrossRefPubMed Barbare JC, Franco D, André T, et al. Should cases of hepatocellular carcinoma be discussed by non specialize multidisciplinary team meetings? Bull Cancer. 2014;101:558–563.CrossRefPubMed
36.
go back to reference Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2013;21:1287–1295.CrossRefPubMedPubMedCentral Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2013;21:1287–1295.CrossRefPubMedPubMedCentral
37.
go back to reference Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858–1868.CrossRefPubMed Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858–1868.CrossRefPubMed
39.
go back to reference Piscaglia F, Svegliati-Baroni G, Barchetti A, HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.CrossRefPubMed Piscaglia F, Svegliati-Baroni G, Barchetti A, HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.CrossRefPubMed
40.
go back to reference Weinmann A, Alt Y, Koch S, et al. Treatment and survival of nonalcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015;1:210.CrossRef Weinmann A, Alt Y, Koch S, et al. Treatment and survival of nonalcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015;1:210.CrossRef
41.
go back to reference Barrault C, Lison H, Roudot-Thoraval F, et al. One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017;29:1155–1160.CrossRefPubMed Barrault C, Lison H, Roudot-Thoraval F, et al. One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. Eur J Gastroenterol Hepatol. 2017;29:1155–1160.CrossRefPubMed
42.
go back to reference Beck F, Guignard R, Léon C, Richard J.-B. Atlas des usages de substances psychoactives 2010. Analyses régionales du Baromètre santé de l’Inpes. Saint-Denis: Inpes, coll. Études santé territoires, 2013 Beck F, Guignard R, Léon C, Richard J.-B. Atlas des usages de substances psychoactives 2010. Analyses régionales du Baromètre santé de l’Inpes. Saint-Denis: Inpes, coll. Études santé territoires, 2013
44.
go back to reference Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373:2223–2233.CrossRefPubMed Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373:2223–2233.CrossRefPubMed
45.
go back to reference Katikireddi SV, Whitley E, Lewsey J, Gray L, Leyland AH. Socioeconomic status as an effect modifier of alcohol consumption and harm: analysis of linked cohort data. Lancet Public Health.. 2017;2:e267–e276.CrossRefPubMedPubMedCentral Katikireddi SV, Whitley E, Lewsey J, Gray L, Leyland AH. Socioeconomic status as an effect modifier of alcohol consumption and harm: analysis of linked cohort data. Lancet Public Health.. 2017;2:e267–e276.CrossRefPubMedPubMedCentral
Metadata
Title
Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C
Authors
Charlotte E. Costentin
Philippe Sogni
Bruno Falissard
Jean-Claude Barbare
Noelle Bendersky
Olivier Farges
Nathalie Goutte
Publication date
01-01-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05724-1

Other articles of this Issue 1/2020

Digestive Diseases and Sciences 1/2020 Go to the issue